Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Testosteronology Society™ Submits Formal Expert Response to FDA Panel on Testosterone Replacement Therapy


News provided by

Testosteronology Society

Feb 06, 2026, 17:25 ET

Share this article

Share toX

Share this article

Share toX


The Testosteronology Society™, a global professional organization dedicated to advancing safe, ethical, and evidence-based testosterone replacement therapy and androgen-focused care through clinician education, certification, standards, and advocacy, announces the submission of its comprehensive expert response to the U.S. Food and Drug Administration's Request for Information on Testosterone Replacement Therapy for Men.

FORT LAUDERDALE, Fla., Feb. 6, 2026 /PRNewswire-PRWeb/ -- The Testosteronology Society™ today announced that it has formally submitted a comprehensive expert response to the Food and Drug Administration Expert Panel on Testosterone Replacement Therapy for Men, following the agency's December 2025 Request for Information seeking clinical, scientific, and regulatory input on testosterone therapy.

The FDA's Request for Information represents a significant moment for the field of androgen-based medicine, signaling a federal reassessment of long-standing policies related to testosterone therapy, including safety warnings, diagnostic criteria, approved indications, and regulatory classification. The Testosteronology Society™ responded with a detailed submission reflecting the real-world clinical experience and scientific expertise of clinicians who specialize in testosterone and androgen care.

When the FDA initiates a formal review of testosterone therapy, it underscores the need for experienced clinical voices at the table. The Testosteronology Society™ exists to ensure that evidence, ethics, and real-world expertise guide the future of care. Dr. O'Connor Testosteronology Society™

Post this

The Testosteronology Society™ submission addresses the FDA's questions across multiple domains, including cardiovascular and metabolic outcomes, thromboembolic risk, musculoskeletal health, mental health considerations, patient selection, timing and duration of therapy, formulation and dosing variables, provider and patient education, and future research priorities. The response also engages broader scientific considerations related to diagnostic thresholds for age-related androgen deficiency, barriers to research and access, and opportunities to modernize data collection and evidence generation.

The Testosteronology Society™ was established to advance excellence in testosterone replacement therapy, men's and women's hormone health, and clinical androgen care through structured education, certification, collaboration, and professional standards. Members of the Testosteronology Society™ include clinicians who manage complex hormone cases and longitudinal patient outcomes, positioning the organization as a critical professional voice in national discussions surrounding modern testosterone therapy.

"This submission reflects the collective expertise of clinicians practicing at the highest level of androgen care," said Dr. Thomas O'Connor, Founder and Chief of the Testosteronology Society™. "When federal regulators ask for expert guidance, it is essential that policy decisions are informed by both rigorous science and real-world clinical experience."

The FDA's Request for Information also explored opportunities for collaboration among healthcare providers, researchers, patients, and industry stakeholders to further define therapeutic uses of testosterone therapy and generate higher-quality evidence supporting safety and efficacy. The Testosteronology Society™ response emphasized the importance of standardized education, advanced clinical training, and professional accountability as foundational elements of responsible expansion.

According to Omar Hajmousa, PharmD, Director of Education and Strategy for the Testosteronology Society™, the submission reflects a deliberate effort to elevate the national conversation surrounding testosterone therapy. "This was not a theoretical exercise. Our response was built from clinical realities, data literacy, and a commitment to advancing standards that protect patients while supporting appropriate access to care."

The Testosteronology Society™ will publish additional information, including the FDA's response to its submission, as it becomes available. As the regulatory landscape evolves, the Testosteronology Society™ remains committed to engaging constructively with regulators and stakeholders to help shape a modern, evidence-based framework for testosterone therapy in the United States.

Clinicians interested in professional leadership, advanced education, certification, and regulatory advocacy related to testosterone and androgen care are encouraged to engage with the Testosteronology Society™.

About the Testosteronology Society™

The Testosteronology Society™ is a global professional organization dedicated to advancing safe, ethical, and evidence-based care for men and women receiving testosterone and other androgens. Through structured education, certification, professional collaboration, and advocacy, the Testosteronology Society™ works to elevate clinical standards, reduce variability in care, and support healthcare professionals who specialize in hormone-based medicine.

To further this mission, the Testosteronology Society™ launched the Testosteronology® Health Portal, a comprehensive digital membership platform designed to address the growing worldwide need for higher-quality hormone education and patient engagement. The Testosteronology® Health Portal provides accessible, evidence-based educational resources that help individuals better understand testosterone, androgens, and hormone-related health conditions, empowering them to become knowledgeable and actively involved participants in their own healthcare.

The Testosteronology® Health Portal serves as a global platform through which Certified Testosteronologists from the Testosteronology Society™ contribute their collective clinical knowledge and real-world experience, providing the public with trusted education, guidance, and resources that empower individuals to become informed and actively involved in their own healthcare decisions. By combining clinician-led education with patient-centered learning, the Testosteronology Society™ and the Testosteronology Health Portal are advancing a global standard of informed care, shared decision-making, and improved health outcomes in testosterone and hormone therapy.

For more information, visit https://testosteronologysociety.com and https://testosteronology.com.

Media Contact

Dr. Thomas O'Connor, Testosteronology Society, 1 860 904-6779, [email protected], https://testosteronologysociety.com

SOURCE Testosteronology Society

Modal title

Testosteronology Society™ Responds To The FDA
Testosteronology Society™ Responds To The FDA
Testosteronology Society™ Responds To The FDA

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.